RETRACTED ARTICLE:Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7713-7717

  Liu, Ling ^a   Zou, Jing ^a   Wang, Qi ^a   Yin, Fu Qiang ^a   Zhang, Wei ^a   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistant tissues and drug sensitive tissues; Epithelial ovarian cancer; MicroRNA microarray chip; Real time PCR

Indexed keywords

MICRORNA;

AGED; BIOLOGY; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS;

EID: 84922392193     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-1970-5     Document Type: TB

References (21)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
2. Samrao D, Wang D, Ough F, Lin YG, Liu S, Menesses T, et al. Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol. 2012;5(6):469–74.
3. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010;116(1):61–5.
4. Ying H, Lv J, Ying T, Yang Q, Ma Y. microRNA and transcription factor mediated regulatory network for ovarian cancer. Tumor Biol. 2013;34(5):3219–25.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
6. Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011;300(1):10–9.
7. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–80.
8. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini G. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.
9. Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, et al. Differential microDNA expression signatures and cells type-specific associated with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 2014;8(1):293–314.
10. Raza U, Zhang JD, Sahin O. MicroRNA expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990–2000.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–8.
12. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207–25.
13. Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. miRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumor Biol. 2013;34(6):3501–8.
14. Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumor Biol. 2011;32(5):1031–47.
15. Burchenal JH, Robinson E, Johnston SF, Kushida MN. The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. Science. 1950;111(2875):116.
16. Boren T, Xiong Y, Hakam A, Wwnham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113(2):249–55.
17. Ying H, Lv J, Ying T, Li J, Yang Q, Ma Y. microRNA and transcription factor mediated regulatory network for ovarian cancer. Tumor Biol. 2013;34(5):3219–25.
18. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012;11(12):2556–65.
19. kip1. Oncol Lett. 2013;6(2):507–12.
20. Li H, Xu H, Shen H, Li H. microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett. 2014;7(1):7183–8.
21. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.